Farletuzumab ecteribulin - CAS 2407465-18-1

Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA) . This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.

Antibody-Drug Conjugates (ADCs)

Antibody-drug Conjugate/ADC Related

2407446

-20°C

Ice Packs

Inhibitory Antibodies